Kala Pharmaceuticals (KALA) Misses Q4 EPS by 9c

Note: EPS may not be comparable

Kala Pharmaceuticals (NASDAQ: KALA) reported Q4 EPS of ($0.46), $0.09 worse than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance